Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female ≥35 years of age at the screening visit~2. Clinical diagnosis of chronic moderate to severe LBP (nonradiculopathic)for ≥3 months~3. History of regular analgesic medication~4. History of inadequate pain relief or intolerance to analgesics used for chronic LBP~5. Willing to discontinue current pain medication~Key Exclusion Criteria:~1. History of lumbosacral radiculopathy within the past 2 years~2. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions~3. Recent use of longer acting pain medications~4. Evidence of destructive arthropathy~5. Other medical conditions that may interfere with participation or accurate assessments during the trial

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasinumab 6 mg SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
- Fasinumab 9 mg SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
- Fasinumab 9 mg IV Q8W and Placebo SC Q4W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
- Placebo SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).